GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (IST:ECILC) » Definitions » Revenue per Share

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) Revenue per Share : ₺9.46 (TTM As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Revenue per Share?

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's revenue per share for the three months ended in Dec. 2023 was ₺4.12. EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was ₺9.46.

During the past 12 months, the average Revenue Per Share Growth Rate of EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS was 87.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 92.40% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 55.70% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Revenue per Share or its related term are showing as below:

IST:ECILC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.8   Med: 4.3   Max: 92.4
Current: 92.4

During the past 13 years, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's highest 3-Year average Revenue Per Share Growth Rate was 92.40% per year. The lowest was -21.80% per year. And the median was 4.30% per year.

IST:ECILC's 3-Year Revenue Growth Rate is ranked better than
97.61% of 919 companies
in the Drug Manufacturers industry
Industry Median: 6.4 vs IST:ECILC: 92.40

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Revenue per Share Historical Data

The historical data trend for EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Revenue per Share Chart

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 1.33 1.61 5.06 9.46

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.40 1.99 1.55 1.80 4.12

Competitive Comparison of EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's PS Ratio distribution charts can be found below:

* The bar in red indicates where EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's PS Ratio falls into.



EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=6479.496/685.260
=9.46

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=2820.476/685.260
=4.12

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺9.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS  (IST:ECILC) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS Revenue per Share Related Terms

Thank you for viewing the detailed overview of EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) Business Description

Traded in Other Exchanges
N/A
Address
Büyükdere Cad. Ali Kaya Sok. No:7, Levent, Istanbul, TUR, 34394
EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS is Turkey-based company operates in the drug business. It is primarily involved in the manufacturing of pharmaceuticals, veterinary drugs, and personal care products. Further, the group is also engaged in the real estate development and leasing commercial property activities. Geographically, all the activities are carried out through the region of Turkey.

EIS Eczacibasi Ilac ve Sinai ve Finansal Yatirimlarnayi ve Ticaret AS (IST:ECILC) Headlines

No Headlines